HHorinouchi· @HHorinouchi · X·· 2 天前评分60
正文 · 机器翻译
🆙#ESMO26 快速口头报告I：#LCSM 转移 🔥BAT8008（TROP2-ADC）联合BAT1308（抗PD-1）一线治疗晚期NSCLC：一项多中心2期研究结果 🎙️Shaodong Hong医生 🔢2631RO 🎯总体：ORR 57.9%，DCR 89.5%，6个月PFS 64.8% 🎯PD-L1 TPS≥50%人群的ORR为83% 🎯≥3级口腔炎仅7.2%，≥3级TRAEs为38.1% ☑️NCT06341114 🔗 https://t.co/E2MIRGnkpb @OncoAlert @Larvol @myESMO @IASLC
热度 0 · 0 赞 · 0 回复 · 0 转发
会议摘要
NCT06341114NCT06341114按 - **标题 / Title：** A Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of the Combination of BAT8008 With BAT1308 in Patients With Advanced Solid Tumors 对上
- **标题 / Title：** A Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of the Combination of BAT8008 With BAT1308 in Patients With Advanced Solid Tumors读摘要原文 →来源：HHorinouchi · x.com